Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Journal article
    Bousquet J, Bewick M, Cano A, Eklund P, Fico G, Goswami N, Guldemond NA, Henderson D, Hinkema MJ, Liotta G, Mair A, Molloy W, Monaco A, Monsonis-Paya I, Nizinska A, Papadopoulos H, Pavlickova A, Pecorelli S, Prados-Torres A, Roller-Wirnsberger RE, Somekh D, Vera-Munoz C, Visser F, Farrell J, Malva J, Ranberg KA, Camuzat T, Carriazo AM, Crooks G, Gutter Z, Iaccarino G, Manuel De Keenoy E, Moda G, Rodriguez-Manas L, Vontetsianos T, Abreu C, Alonso J, Alonso-Bouzon C, Ankri J, Arredondo MT, Avolio F, Bedbrook A, Bialoszewski AZ, Blain H, Bourret R, Cabrera-Umpierrez MF, Catala A, O'Caoimh R, Cesari M, Chavannes NH, Correia-Da-Sousa J, Dedeu T, Ferrando M, Ferri M, Fokkens WJ, Garcia-Lizana F, Guerin O, Hellings PW, Haahtela T, Illario M, Inzerilli MC, Carlsen KCL, Kardas P, Keil T, Maggio M, Mendez-Zorrilla A, Menditto E, Mercier J, Michel JP, Murray R, Nogues M, O'Byrne-Maguire I, Pappa D, Parent AS, Pastorino M, Robalo-Cordeiro C, Samolinski B, Siciliano P, Teixeira AM, Tsartara SI, Valiulis A, Vandenplas O, Vasankari T, Vellas B, Vollenbroek-Hutten M, Wickman M, Yorgancioglu A, Zuberbier T, Barbagallo M, Canonica GW, Klimek L, Maggi S, Aberer W, Akdis C, Adcock IM, Agache I, Albera C, Alonso-Trujillo F, Angel Guarcia M, Annesi-Maesano I, Apostolo J, Arshad SH, Attalin V, Avignon A, Bachert C, Baroni I, Bel E, Benson M, Bescos C, Blasi F, Barbara C, Bergmann KC, Bernard PL, Bonini S, Bousquet PJ, Branchini B, Brightling CE, Bruguiere V, Bunu C, Bush A, Caimmi DP, Calderon MA, Canovas G, Cardona V, Carlsen KH, Cesario A, Chkhartishvili E, Chiron R, Chivato T, Chung KF, D'Angelantonio M, De Carlo G, Cholley D, Chorin F, Combe B, Compas B, Costa DJ, Costa E, Coste O, Coupet A-L, Crepaldi G, Custovic A, Dahl R, Dahlen SE, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Du Toit G, Dubakiene R, Dupeyron A, Emuzyte R, Fiocchi A, Wagner A, Fletcher M, Fonseca J, Fougere B, Gamkrelidze A, Garces G, Garcia-Aymeric J, Garcia-Zapirain B, Gemicioglu B, Goudeet al., 2017,

    Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

    , Journal of Nutrition, Health and Aging, Vol: 21, Pages: 92-104, ISSN: 1279-7707

    The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups’ new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The outcomes and impact of synergies are using the Monitoring and Assessment Framework for the EIP on AHA (MAFEIP). Eight proposals for synergies have been approved by the Task Force: Five cross-cutting synergies which can be used for all current and future synergies as they consider overarching domains (appropriate polypharmacy, citizen empowerment, teaching and coaching on AHA, deployment of synergies to EU regions, Responsible Research and Innovation), and three cross-cutting synergies focussing on current Action Group activities (falls, frailty, integrated care and chronic respiratory diseases).

  • Conference paper
    Bonvini SJ, Adcock JJ, Dubuis E, Wortley M, Vriens J, Voets T, Birrell MA, Belvisi MGet al., 2017,

    Trpm3: A Regulator Of Airway Sensory Nerves And Respiratory Reflexes Via Distinct Mechanisms

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Alqurashi Y, Moss J, Nakamura T, Goverdovsky V, Polkey M, Mandic D, Morrell MJet al., 2017,

    The Efficacy Of In-Ear Electroencephalography (eeg) To Monitor Sleep Latency And The Impact Of Sleep Deprivation

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Donaldson GC, Wedzicha JA, 2017,

    Rise In Blood Neutrophils, And Falls In Eosinophils, Over Time Is Associated With Mortality In COPD: A Joint Model Analysis

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Smith JA, McGarvey L, Morice AH, Birring SS, Wedzicha JA, Notari M, Segarra R, Seoane B, Jarreta Det al., 2017,

    Efficacy Of Aclidinium Bromide 400 μg On The Relief Of Cough Symptoms In Symptomatic Patients With Chronic Obstructive Pulmonary Disease: A Cough Severity Subgroup Analysis

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Book chapter
    Wortley MA, Birrell MA, Belvisi MG, 2017,

    Drugs Affecting TRP Channels

    , PHARMACOLOGY AND THERAPEUTICS OF ASTHMA AND COPD, Editors: Page, Barnes, Publisher: SPRINGER-VERLAG BERLIN, Pages: 213-241, ISBN: 978-3-319-52173-2
  • Conference paper
    Allinson JP, Donaldson GC, Wedzicha JA, 2017,

    Is The Absence Of Purulence Sputum At Exacerbation Useful For Guiding Long-Term Therapy?

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Donaldson GC, Wedzicha JA, 2017,

    Rate Of Deterioration In Sgrq Is Independently Predictive Of Mortality In COPD

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Donaldson GC, Allinson JP, Finney L, Wedzicha JAet al., 2017,

    Not All Treated COPD Exacerbations Are Associated With A Raised C-Reactive Protein

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Thorley A, Ogger P, Legorburo-Schofield M, Tetley T, Wollin Let al., 2017,

    Nintedanib Effectively Inhibits Carbon Nanotube-Induced Fibrotic Responses In Human Alveolar Epithelial Cells, Fibroblasts And Pulmonary Microvascular Endothelial Cells

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Conference paper
    Smith JA, McGarvey L, Morice AH, Birring SS, Wedzicha JA, Notari M, Segarra R, Seoane B, Jarreta Det al., 2017,

    The Effect Of Aclidinium Bromide 400 μg On The Relief Of Daily Symptoms Associated With Chronic Obstructive Pulmonary Disease, Including Cough

    , International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
  • Journal article
    Law M, Sweeting MJ, Donaldson GC, Wedzicha JAet al., 2016,

    Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: the resultant bias in treatment effect estimation

    , Pharmaceutical Statistics, Vol: 16, Pages: 201-209, ISSN: 1539-1604

    In trials comparing the rate of chronic obstructive pulmonary disease exacerbation between treatment arms, the rate is typically calculated on the basis of the whole of each patient's follow-up period. However, the true time a patient is at risk should exclude periods in which an exacerbation episode is occurring, because a patient cannot be at risk of another exacerbation episode until recovered. We used data from two chronic obstructive pulmonary disease randomized controlled trials and compared treatment effect estimates and confidence intervals when using two different definitions of the at-risk period. Using a simulation study we examined the bias in the estimated treatment effect and the coverage of the confidence interval, using these two definitions of the at-risk period. We investigated how the sample size required for a given power changes on the basis of the definition of at-risk period used. Our results showed that treatment efficacy is underestimated when the at-risk period does not take account of exacerbation duration, and the power to detect a statistically significant result is slightly diminished. Correspondingly, using the correct at-risk period, some modest savings in required sample size can be achieved. Using the proposed at-risk period that excludes recovery times requires formal definitions of the beginning and end of an exacerbation episode, and we recommend these be always predefined in a trial protocol.

  • Journal article
    Beeh KM, Burgel P-R, Franssen FME, Luis Lopez-Campos J, Loukides S, Hurst JR, Flezar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Stallberg B, Kostikas K, Wedzicha JAet al., 2016,

    How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

    , AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 196, Pages: 139-149, ISSN: 1073-449X

    Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease. Several studies have documented that long-acting bronchodilators can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting β2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroid combinations in patients at low and high risk for these events. In this review, small groups of experts critically evaluated mechanisms potentially responsible for the increased benefit of LABA/LAMA combinations over single long-acting bronchodilators or LABA/inhaled corticosteroids in decreasing exacerbation. These included effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus production with impaired mucociliary clearance, and symptom severity. The data assembled and analyzed by each group were reviewed by all authors and combined into this manuscript. Available clinical results support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom severity may all contribute to decreasing exacerbations. Although preclinical studies suggest LABAs and LAMAs have antiinflammatory effects, such effects have not been demonstrated yet in patients with chronic obstructive pulmonary disease.

  • Journal article
    Johnson CL, Rogers DF, 2016,

    WHY IS ERDOSTEINE RECOMMENDED AS A TREATMENT FOR ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS? A SYSTEMATIC REVIEW OF CLINICAL TRIALS

    , THORAX, Vol: 71, Pages: A157-A157, ISSN: 0040-6376
  • Journal article
    Eastwood PR, Morrell MJ, Malhotra A, 2016,

    Update in respiratory sleep disorders: Prologue to a modern review series

    , RESPIROLOGY, Vol: 22, Pages: 17-18, ISSN: 1323-7799
  • Journal article
    Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JAet al., 2016,

    EARLY-LIFE RESPIRATORY TRACT INFECTION AND ADULT SUSCEPTIBILITY TO CHRONIC MUCUS HYPERSECRETION - A PROSPECTIVE 64 YEAR NATIONAL BIRTH COHORT STUDY

    , THORAX, Vol: 71, Pages: A1-A2, ISSN: 0040-6376
  • Conference paper
    Rasiah MG, Michaeloudes C, Svermova T, Nikolakopoulou Z, Creagh-Brown B, Bhavsar PK, Burke-Gaffney Aet al., 2016,

    PLASMA SYNDECAN-1 LEVEL AS A PREDICTIVE MARKER OF VASOPLEGIA ASSOCIATED WITH SURGERY REQUIRING CARDIOPULMONARY BYPASS AND POSSIBLE INVOLVEMENT OF OXIDATIVE STRESS

    , British Thoracic Society Winter Meeting 2016, Publisher: BMJ PUBLISHING GROUP, Pages: A9-A9, ISSN: 0040-6376
  • Conference paper
    McErlean P, Kelly A, Dhariwal J, Watson J, Jurdzinski N, Smith J, Solari R, Edwards MR, Van Oosterhout A, Johnston SL, Lavender Pet al., 2016,

    EPIGENETIC LANDSCAPE OF THE ASTHMATIC AIRWAYS

    , British Thoracic Society Winter Meeting 2016, Publisher: BMJ PUBLISHING GROUP, Pages: A214-A214, ISSN: 0040-6376
  • Conference paper
    Finney LJ, Belchamber KBR, Mallia P, Johnston SL, Donnelly LE, Wedzicha JAet al., 2016,

    HUMAN RHINOVIRUS IMPAIRS THE INNATE IMMUNE RESPONSE TO BACTERIA IN MONOCYTE DERIVED MACROPHAGES FROM PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    , British Thoracic Society Winter Meeting 2016, Publisher: BMJ PUBLISHING GROUP, Pages: A2-A2, ISSN: 0040-6376
  • Journal article
    Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, Stanciu LAet al., 2016,

    Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro

    , Antiviral Research, Vol: 137, Pages: 93-101, ISSN: 1872-9096

    BACKGROUND: By modulating the antiviral immune response via vitamin D receptor, the active form of vitamin D (1,25-dihydroxyvitamin D, calcitriol) could play a central role in protection against respiratory virus infections. This in vitro study tested the hypothesis that respiratory viruses modulate vitamin D receptor expression in human bronchial epithelial cells and this modulation affects the antiviral response to exogenous vitamin D. METHODS: Human primary bronchial epithelial cells were infected with rhinoviruses and respiratory syncytial virus in the presence or absence of vitamin D. Expression of vitamin D receptor, 1α-hydroxylase (1α(OH)ase), 24-hydroxylase (24(OH)ase), innate interferons, interferon stimulated genes and cathelicidin were measured by quantitative polymerase chain reaction. The antiviral effect of vitamin D on rhinovirus replication was determined by measurement of virus load. A direct inactivation assay was used to determine the antiviral activity of cathelicidin. RESULTS: Both RV and RSV decreased vitamin D receptor and 24(OH)ase and, in addition, RSV increased 1α(OH)ase expression in epithelial cells. Vitamin D decreased rhinovirus replication and release, and increased rhinovirus-induced interferon stimulated genes and cathelicidin. Furthermore, cathelicidin had direct anti-rhinovirus activity. CONCLUSIONS: Despite lower vitamin D receptor levels in rhinovirus-infected epithelial cells, exogenous vitamin D increased antiviral defences most likely via cathelicidin and innate interferon pathways.

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=854&limit=20&page=16&respub-action=search.html Current Millis: 1711676648275 Current Time: Fri Mar 29 01:44:08 GMT 2024